Planep作用功效

It is a new type of selective aldosterone receptor antagonist. It was approved for clinical use by the State Food and Drug Administration in 2002. The pure product is white or off-white crystal. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

Planep effects

The clinical trial uses losartan as a reference to evaluate the clinical efficacy and safety of Planep in the treatment of mild to moderate essential hypertension. Methods: 72 patients with mild to moderate hypertension were randomly divided into: ambulatory blood pressure group, losartan group, and eplerenone group, with 24 cases in each group. The losartan group and the Planep group used a double-simulation and positive drug parallel control method, and received losartan and eplerenone treatment respectively. After 4 weeks of treatment, if the blood pressure did not reach the target, the drug dose was doubled and the treatment continued for 4 weeks; if the blood pressure reached the target, the original dose was maintained and the treatment continued for 4 weeks. The ambulatory blood pressure group took eplerenone 25 mg once a day.

The results showed that after 8 weeks of treatment, compared with before treatment, the average sitting diastolic blood pressure in the Planep group decreased by (13.32±4.57) mmHg and in the Losartan group by (10.90±5.64) mmHg. There was no statistically significant difference between the two groups. After 8 weeks of treatment, compared with before treatment, the average sitting systolic blood pressure of the Planep group decreased by (23.56±9.39) mmHg, and that of the Losartan group decreased by (18.67±7.00) mmHg. There was no statistically significant difference between the two groups; the average sitting systolic blood pressure of the Planep group and the Losartan group reached the standard. They were 83.33% and 91.30% respectively, with no statistically significant difference between the two groups; the effective rates of blood pressure reduction were 75.0% and 60.9%, respectively, and the total effective rates of blood pressure reduction were 91.7% and 91.3%, respectively. There was no statistically significant difference between the groups in the effective rate of blood pressure reduction and the total effective rate of blood pressure reduction.